Tetracyclines: Drugs with Huge Therapeutic Potential

被引：144

作者：

Bahrami, F. ^{[1
]}

Morris, D. L. ^{[1
]}

Pourgholami, M. H. ^{[1
]}

机构：

[1] Univ New S Wales, Dept Surg, St George Hosp SESIAHS, Sydney, NSW 2217, Australia

来源：

MINI-REVIEWS IN MEDICINAL CHEMISTRY | 2012年 / 12卷 / 01期

关键词：

Tetracyclines; minocycline; doxycycline; antibiotic; inflammation; neurodegenerative diseases; stroke; matrix metalloproteinase; cytokines; apoptosis; MATRIX-METALLOPROTEINASE INHIBITORS; CELL-DEATH; CYTOCHROME-C; MINOCYCLINE; DOXYCYCLINE; DISEASE; CANCER; ACNE; NEUROPROTECTION; MITOCHONDRIA;

D O I：

10.2174/138955712798868977

中图分类号：

R914 [药物化学];

学科分类号：

100705 [微生物与生化药学];

摘要：

Tetracyclines are an amazing class of chemical agents with multiple therapeutic potential. Structural modification of the original natural tetracyclines led to the synthesis and development of doxycycline and minocycline, compounds with higher lipophilicity, better oral pharmacokinetics and higher potency. Due to diverse pharmacological properties, these drugs are now under extensive investigation for use in the treatment of various disparate diseases. In recent years, several studies have conclusively reported anti-inflammatory, immune-modulating and neuroprotective effects of these compounds. There are currently over 200 ongoing clinical trials on tetracyclines. These studies extend over a wide range of diseases including dermatological diseases, behavior and mental disorders, immune system disorders, cardiovascular diseases, and cancer. In this review we will discuss the chemistry and pharmacology of these agents, and describe how their inhibitory effect on matrix metalloproteinase and on pro-inflammatory cytokines has kindled renewed interest in them. Based on the reports from pre-clinical and clinical trials, the therapeutic potential and application of tetracyclines may well be redefined and extensively extended.

引用

页码：44 / 52

页数：9

共 76 条

[1]

Chemically modified tetracyclines as inhibitors of matrix metalloproteinases [J].

Acharya, MR ;

Venitz, E ;

Figg, WD ;

Sparreboom, A .

DRUG RESISTANCE UPDATES, 2004, 7 (03) :195-208

[2]

Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer - Modern target but ancient solution [J].

Aggarwal, Bharat B. ;

Sethi, Gautam ;

Ahn, Kwang Seok ;

Sandur, Santosh K. ;

Pandey, Manoj K. ;

Kunnumakkara, Ajaikumar B. ;

Sung, Bokyung ;

Ichikawa, Haruyo .

SIGNAL TRANSDUCTION PATHWAYS, PT B: STRESS SIGNALING AND TRANSCRIPTIONAL CONTROL, 2006, 1091 :151-169

[3]

The tetracycline:Mg2+ complex:: A molecular mechanics force field [J].

Aleksandrov, Alexey ;

Simonson, Thomas .

JOURNAL OF COMPUTATIONAL CHEMISTRY, 2006, 27 (13) :1517-1533

[4]

Minocycline chelates Ca2+, binds to membranes, and depolarizes mitochondria by formation of Ca2+-dependent ion channels [J].

Antonenko, Yuri N. ;

Rokitskaya, Tatyana I. ;

Cooper, Arthur J. L. ;

Krasnikov, Boris F. .

JOURNAL OF BIOENERGETICS AND BIOMEMBRANES, 2010, 42 (02) :151-163

[5]

Arvelo Francisco, 2006, Invest. clín, V47, P185

[6]

PLASMID-MEDIATED TETRACYCLINE RESISTANCE IN ESCHERICHIA-COLI INVOLVES INCREASED EFFLUX OF THE ANTIBIOTIC [J].

BALL, PR ;

SHALES, SW ;

CHOPRA, I .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1980, 93 (01) :74-81

[7]

RELATION BETWEEN LIPOPHILICITY AND PHARMACOLOGICAL BEHAVIOR OF MINOCYCLINE, DOXYCYCLINE, TETRACYCLINE, AND OXYTETRACYCLINE IN DOGS [J].

BARZA, M ;

BROWN, RB ;

SHANKS, C ;

GAMBLE, C ;

WEINSTEIN, L .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1975, 8 (06) :713-720

[8]

The Antibiotics Doxycycline and Minocycline Inhibit the Inflammatory Responses to the Lyme Disease Spirochete Borrelia burgdorferi [J].

Bernardino, Andrea L. F. ;

Kaushal, Deepak ;

Philipp, Mario T. .

JOURNAL OF INFECTIOUS DISEASES, 2009, 199 (09) :1379-1388

[9]

Angiogenic targets for potential disorders [J].

Bhadada, Shraddha V. ;

Goyal, Bhoomika R. ;

Patel, Mayur M. .

FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2011, 25 (01) :29-47

[10]

Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients [J].

BlumDegen, D ;

Muller, T ;

Kuhn, W ;

Gerlach, M ;

Przuntek, H ;

Riederer, P .

NEUROSCIENCE LETTERS, 1995, 202 (1-2) :17-20

← 1 2 3 4 5 6 7 8 →